proline has been researched along with eflornithine in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (25.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Chandar, N; Nagarajan, B | 1 |
Brockway, PD; Gall, DG; Hardin, JA; Johnson, LR; Madsen, K | 1 |
Cheever, AW; Fuentes, JM; Hesse, M; La Flamme, AC; Modolell, M; Pearce, EJ; Schito, M; Wynn, TA | 1 |
Perišić, O | 1 |
4 other study(ies) available for proline and eflornithine
Article | Year |
---|---|
Host liver changes in leukemic mice: effect of alpha-difluoromethyl ornithine, an inhibitor of polyamine synthesis.
Topics: Animals; beta-N-Acetylhexosaminidases; Eflornithine; Female; gamma-Glutamyltransferase; Glutathione; Hexosaminidases; Leukemia P388; Leukemia, Experimental; Liver; Mice; Mice, Inbred DBA; Ornithine; Polyamines; Proline | 1984 |
Polyamines alter intestinal glucose transport.
Topics: Animals; Biological Transport; Cycloheximide; Eflornithine; Glucose; Intestinal Absorption; Kinetics; Membrane Fluidity; Membrane Lipids; Microvilli; Polyamines; Proline; Rabbits; Sodium | 1995 |
Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism.
Topics: Animals; Arginase; Arginine; Cells, Cultured; Disease Models, Animal; Eflornithine; Enzyme Activation; Enzyme Induction; Enzyme Inhibitors; Female; Granuloma; Interleukin-12; Liver; Liver Cirrhosis; Lung Diseases, Parasitic; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Mycobacterium avium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Ornithine Decarboxylase Inhibitors; Ovum; Proline; Schistosomiasis mansoni; Th1 Cells; Th2 Cells; Tuberculosis; Up-Regulation | 2001 |
Recognition of Potential COVID-19 Drug Treatments through the Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of Kinetically Active Residues.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Viral; Antigen-Antibody Reactions; Antiviral Agents; Betacoronavirus; Binding Sites; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Eflornithine; Humans; Hydrophobic and Hydrophilic Interactions; Ivermectin; L-Lactate Dehydrogenase; Models, Molecular; Molecular Docking Simulation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Proline; Protein Binding; Protein Conformation; Protein Interaction Mapping; Receptors, Glycine; Saposins; SARS-CoV-2; Sofosbuvir; Spike Glycoprotein, Coronavirus; Structure-Activity Relationship | 2020 |